The approval of the once-daily injection (18 mg/3 mL), as an adjunct ... "Today's approval underscores the FDA's continued commitment to advancing patient access to safe, effective, and high ...

Last week, the U.S. Food and Drug Administration (FDA) approved the first generic version of liraglutide injection, a game-changing development that promises to improve patient access to life ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release. Nivolumab and ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The approval of the once-daily injection (18 mg/3 mL), as an adjunct ... dyspepsia and constipation. “The FDA supports development of complex generic drugs, such as GLP-1s, by funding research ...